Abstract
The mechanisms that enable immune evasion at metastatic sites are poorly understood. We show that the Polycomb Repressor Complex 1 (PRC1) drives colonization of the bones and visceral organs in double-negative prostate cancer (DNPC). In vivo genetic screening identifies CCL2 as the top prometastatic gene induced by PRC1. CCL2 governs self-renewal and induces the recruitment of M2-like tumor-associated macrophages and regulatory T cells, thus coordinating metastasis initiation with immune suppression and neoangiogenesis. A catalytic inhibitor of PRC1 cooperates with immune checkpoint therapy to reverse these processes and suppress metastasis in genetically engineered mouse transplantation models of DNPC. These results reveal that PRC1 coordinates stemness with immune evasion and neoangiogenesis and point to the potential clinical utility of targeting PRC1 in DNPC. Su et al. show that PRC1 drives metastasis of androgen receptor and neuroendocrine double-negative prostate cancers by regulating CCL2 expression. CCL2 governs self-renewal and recruitment of TAM and Treg. PRC1 inhibition combined with immune checkpoint blockade reverses these processes and suppresses metastasis.
Original language | English (US) |
---|---|
Pages (from-to) | 139-155.e10 |
Journal | Cancer cell |
Volume | 36 |
Issue number | 2 |
DOIs | |
State | Published - Aug 12 2019 |
Keywords
- MDSCs
- Tregs
- angiogenesis
- combination therapy
- epigenetics
- immune evasion
- immune microenvironment
- metastasis
- preclinical compound
- stemness
ASJC Scopus subject areas
- Oncology
- Cell Biology
- Cancer Research
MD Anderson CCSG core facilities
- Research Animal Support Facility
- Small Animal Imaging Facility